Literature DB >> 6529527

Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.

S Jawad, A Richens, J Oxley.   

Abstract

The pharmacokinetics of clobazam were studied in six healthy volunteers and six age and sex matched enzyme-induced epileptic patients. In the epileptic patients the area under the plasma concentration-time curve for clobazam was significantly smaller and the area under the plasma concentration-time curve for N-desmethylclobazam was significantly greater than in the healthy volunteers. Plasma N-desmethylclobazam concentrations were found to be much higher than those of clobazam in the epileptic patients, raising the possibility that the antiepileptic properties of clobazam are to be attributed more to its metabolite than the parent drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529527      PMCID: PMC1463679          DOI: 10.1111/j.1365-2125.1984.tb02558.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

2.  Kinetics and metabolism of clobazam in animals and man.

Authors:  M Volz; O Christ; H M Kellner; H Kuch; H W Fehlhaber; D Gantz; P Hajdu; F Cavagna
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Pharmacokinetics of single and multiple doses of clobazam in humans.

Authors:  W Rupp; M Badian; O Christ; P Hajdú; R D Kulkarni; K Taeuber; M Uihlein; R Bender; O Vanderbeke
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Effect of phenobarbital on the in vitro metabolism of diazepam in several animal species.

Authors:  F Marcucci; R Fanelli; E Mussini; S Garattini
Journal:  Biochem Pharmacol       Date:  1970-05       Impact factor: 5.858

5.  Interindividual differences in rates of drug oxidation in man.

Authors:  D S Davies; S S Thorgeirsson; A Breckenridge; M Orme
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

6.  Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients.

Authors:  G Tedeschi; R Riva; A Baruzzi
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

7.  Pharmacology of anti-anxiety drugs with special reference to clobazam.

Authors:  S Fielding; I Hoffmann
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

8.  Clobazam kinetics: intrasubject variability and effect of food on adsorption.

Authors:  M Divoll; D J Greenblatt; D A Ciraulo; S K Puri; I Ho; R I Shader
Journal:  J Clin Pharmacol       Date:  1982-01       Impact factor: 3.126

9.  The effect of enzyme induction on diazepam metabolism in man.

Authors:  E E Ohnhaus; B K Park; J P Colombo; P Heizmann
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

10.  Time-course of interaction between carbamazepine and clonazepam in normal man.

Authors:  A A Lai; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

View more
  11 in total

Review 1.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  PharmGKB summary: clobazam pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Steven Leeder; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-04       Impact factor: 2.089

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.

Authors:  Sachiyo Hashi; Ikuko Yano; Mai Shibata; Satohiro Masuda; Masako Kinoshita; Riki Matsumoto; Akio Ikeda; Ryosuke Takahashi; Kazuo Matsubara
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

6.  The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam.

Authors:  T Pullar; D Edwards; J R Haigh; S Peaker; M P Feely
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

7.  Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy.

Authors:  T Pullar; J R Haigh; S Peaker; M P Feely
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

8.  N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

Authors:  J R Haigh; T Pullar; J P Gent; C Dailley; M Feely
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

9.  The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.

Authors:  J J Muñoz; R E De Salamanca; C Diaz-Obregón; F L Timoneda
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

10.  A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Pharm Res       Date:  2014-07-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.